Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

3.490 +0.010 (+0.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Preview: Fulcrum Therapeutics's Earnings
Via Benzinga
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
The Latest Analyst Ratings for Fulcrum Therapeutics
Via Benzinga
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:FULC Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulcrum Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 09/14/2023 -- Certain directors of Fulcrum Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food... 
Via FinancialNewsMedia
Exposures Product Safety
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Enrolled 260 patients; topline data expected in the fourth quarter of 2024 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Dollar Tree, Burlington Stores, Opera And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones falling over 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Splunk Are Trading Higher By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Electriq Power Holdings, Inc. (NYSE: ELIQ) shares jumped 130.3% to $3.3847. 
Via Benzinga
Fulcrum Therapeutics To Rally Around 120%? FDA Update Removes Overhang On Pivotal Program
Tuesday, the FDA lifted the clinical hold on Fulcrum Therapeutics Inc's (NASDAQ: FULC) Investigational New Drug (IND) application for FTX-6058 for the potential treatment of  
Via Benzinga
Exposures Product Safety
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial Fossil Fuels US Equities
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease. 
Via Benzinga
Exposures Product Safety
Dow Falls Over 100 Points; US Existing Home Sales Decline In July
U.S. stocks traded mixed midway through trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.32% to 34,354.22 while the NASDAQ rose 0.52% to 13,567.52. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Why Is Fulcrum Therapeutics Stock Surging Today?
Fulcrum Therapeutics Inc (NASDAQ: FULC) shares are trading higher after the FDA lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of  
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
Via Benzinga
Fulcrum Therapeutics, AMTD Digital, Hasbro And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
BLNK Stock Alert: Blink Charging Signs Deal to Bring EV Charging to McDonald’s
Blink Charging (BLNK) stock is on the move Tuesday after the EV charging company signed a deal that brings its services to McDonald's (MCD). 
Via InvestorPlace
US Stocks Mixed; Lowe's Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.07% to 34,439.33 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
APP Stock Price Predictions: Is AppLovin Really Worth $50?
Applovin (APP) stock is in the news Tuesday after the stock got a new price target from Jefferies analyst Andrew Uerkwitz. 
Via InvestorPlace
Why Is Fulcrum Therapeutics (FULC) Stock Up 43% Today?
Fulcrum Therapeutics (FULC) stock is on the rise Tuesday after the FDA removed a clinical hold on its sickle-cell disease candidate. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.